Plasmatech Biopharmaceuticals Inc Stock Nasdaq
Stocks
US72754H1095
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-29 | Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Growth Benchmark | CI |
| 06-28 | Abeona Therapeutics Inc.(NasdaqCM:ABEO) added to Russell 2000 Value-Defensive Index | CI |
| Market Cap | 400M 350M 325M 299M 565M 38.24B 576M 3.87B 1.52B 18.78B 1.5B 1.47B 64.85B | P/E 2026 * |
-9.49x | P/E 2027 * | -100x |
|---|---|---|---|---|---|
| Enterprise Value | 400M 350M 325M 299M 565M 38.24B 576M 3.87B 1.52B 18.78B 1.5B 1.47B 64.85B | EV / Sales 2026 * |
6.1x | EV / Sales 2027 * | 2.96x |
| Free-Float |
79.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Plasmatech Biopharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 50 | 2021-10-14 |
Joseph Vazzano
DFI | Director of Finance/CFO | 42 | 2022-03-13 |
James A. Gow
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Keith Goldan
BRD | Director/Board Member | 55 | 2026-03-31 |
Mark Alvino
BRD | Director/Board Member | 58 | 2006-02-28 |
Faith Charles
BRD | Director/Board Member | 64 | 2021-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22% | +2.04% | +16.79% | -8.03% | 67.61B | |
| -0.63% | -7.39% | +37.82% | +199.82% | 51.6B | |
| +0.36% | +40.00% | +40.00% | +40.00% | 43B | |
| +0.44% | -2.10% | -49.66% | -54.01% | 40.94B | |
| +4.96% | +0.27% | +55.75% | -24.80% | 29.4B | |
| -1.85% | -18.08% | +99.20% | -47.07% | 27.09B | |
| -2.12% | -1.20% | +66.54% | +84.42% | 23.32B | |
| -0.67% | -1.55% | +10.61% | +172.48% | 19.92B | |
| -2.12% | -3.92% | +61.37% | +130.60% | 16.91B | |
| Average | -0.23% | -2.60% | +37.60% | +54.82% | 35.53B | |
| Weighted average by Cap. | -0.08% | -2.32% | +30.96% | +46.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 65.51M 57.46M 53.22M 48.97M 92.62M 6.27B 94.42M 634M 249M 3.08B 246M 241M 10.63B | 135M 118M 110M 101M 191M 12.92B 194M 1.31B 512M 6.34B 507M 496M 21.9B |
| Net income | -42.25M -37.06M -34.33M -31.58M -59.74M -4.04B -60.9M -409M -160M -1.99B -159M -155M -6.86B | -2.1M -1.84M -1.71M -1.57M -2.97M -201M -3.03M -20.34M -7.98M -98.76M -7.89M -7.72M -341M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
